Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access and country-specific regulatory environments - - Ionis to independently commercialize zilganersen in the U.S.